Acknowledgement
This work was supported by the Korea University Guro Hospital (Korea Research-Driven Hospital) grant (No. O2208131 and O2206871), Korea Basic Science Institute (National Research Facilities and Equipment Center) grant (No.2021R1A6C101C570) funded by the Ministry of Education, and National Research Foundation of Korea (NRF) grant (NRF-2022M3A9I2017241) funded by the Ministry of Science and ICT, Republic of Korea.
References
- World Health Organization. Tracking SARS-CoV-2 variants [Internet]. Available at: https://www.who.int/activities/tracking-SARS-CoV-2-variants [accessed on 28 June 2023].
- Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair MS, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 2022;602:676-681. https://doi.org/10.1038/s41586-021-04388-0
- Collier AY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, Gallup L, Rowe M, Schonberg E, Thai S, et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N Engl J Med 2023;388:565-567. https://doi.org/10.1056/NEJMc2213948
- Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, et al. A bivalent Omicron-containing booster vaccine against COVID-19. N Engl J Med 2022;387:1279-1291. https://doi.org/10.1056/NEJMoa2208343
- Korea Disease Control and Prevention Agency. Press release: Jun 21, 2023 [Internet]. Available at: https://www.kdca.go.kr/filepath/boardSyview.es?bid=0015&list_no=722804&seq=2 [accessed on 28 June 2023].
- Korea Disease Control and Prevention Agency. Press release: Feb 15, 2023 [Internet]. Available at: https://www.kdca.go.kr/filepath/boardSyview.es?bid=0015&list_no=721886&seq=2 [accessed on 28 June 2023].
- World Health Organization. TAG-VE statement on Omicron sublineages BQ.1 and XBB [Internet]. Available at: https://www.who.int/news/item/27-10-2022-tag-ve-statement-on-omicron-sublineages-bq.1-and-xbb [accessed on 13 June 2023].
- Centers for Disease Control and Prevention. COVID data tracker: variant proportions [Internet]. Available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions [accessed on 13 June 2023].
- World Health Organization. Statement on the antigen composition of COVID-19 vaccines [Internet]. Available at: https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-ofcovid-19-vaccines [accessed on 13 June 2023].
- Food and Drug Administration. Updated COVID-19 vaccines for use in the United States beginning in fall 2023 [Internet]. Available at: https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccinesuse-united-states-beginning-fall-2023?source=email [accessed on 17 June 2023].
- Sun D, Hsu A, Bogardus L, Rubinstein LJ, Antonello JM, Gurney KB, Whiteman MC, Dellatore S. Development and qualification of a fast, high-throughput and robust imaging-based neutralization assay for respiratory syncytial virus. J Immunol Methods 2021;494:113054.
- Whiteman MC, Bogardus L, Giacone DG, Rubinstein LJ, Antonello JM, Sun D, Daijogo S, Gurney KB. Virus reduction neutralization test: a single-cell imaging high-throughput virus neutralization assay for dengue. Am J Trop Med Hyg 2018;99:1430-1439. https://doi.org/10.4269/ajtmh.17-0948
- Grist NR, Bell EJ, Ross CA. Diagnostic methods in clinical virology, 2nd ed. Philadelphia, PA: J. B. Lippincott; 1974.
- Cov-Lineages. Lineage list [Internet]. Available at: https://cov-lineages.org/lineage_list.html [accessed on 16 June 2023].
- Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, Wang J, An R, Chen X, Zhang N, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 2023;614:521-529.
- Liu Y, Wang Z, Zhuang X, Zhang S, Chen Z, Zou Y, Sheng J, Li T, Tai W, Yu J, et al. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. Nat Commun 2023;14:2179.
- Liu S, Liang Z, Nie J, Gao WB, Li X, Zhang L, Yu Y, Wang Y, Huang W. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1. Emerg Microbes Infect 2023;12:2225638.
- Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 2023;186:279-286.e8. https://doi.org/10.1016/j.cell.2022.12.018
- Miller J, Hachmann NP, Collier AY, Lasrado N, Mazurek CR, Patio RC, Powers O, Surve N, Theiler J, Korber B, et al. Substantial neutralization escape by SARS-CoV-2 Omicron variants BQ.1.1 and XBB.1. N Engl J Med 2023;388:662-664. https://doi.org/10.1056/NEJMc2214314
- Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M, Cooper D, Yang Q, Cai H, Muik A, et al. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N Engl J Med 2023;388:854-857.
- Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, Porter-Morrison A, Hentenaar IT, Yamamoto F, Godbole S, et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster. N Engl J Med 2023;388:183-185. https://doi.org/10.1056/NEJMc2214293
- Korea Disease Control and Prevention Agency. Neutralizing antibody against omicron subvariants (BA.1, BA.1.1, and BA.2). Public Health Wkly Rep 2022;15:1460-1462.
- Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, Xie X, Shi PY. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med 2023;29:344-347. https://doi.org/10.1038/s41591-022-02162-x
- Lasrado N, Collier AY, Miller J, Hachmann NP, Liu J, Sciacca M, Wu C, Anand T, Bondzie EA, Fisher JL, et al. Waning immunity against XBB.1.5 following bivalent mRNA boosters. Preprint at https://www.biorxiv.org/content/10.1101/2023.01.22.525079 (2023).
- Wang Q, Bowen A, Tam AR, Valdez R, Stoneman E, Mellis IA, Gordon A, Liu L, Ho DD. SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster. Lancet Infect Dis 2023;23:527-528. https://doi.org/10.1016/S1473-3099(23)00181-0
- Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, et al. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat Med 2023;29:2334-2346. https://doi.org/10.1038/s41591-023-02503-4
- Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, Norwood C, Nyhoff LE, Edara VV, Floyd K, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep Med 2021;2:100354.
- Traut CC, Blankson JN. Bivalent mRNA vaccine-elicited SARS-CoV-2 specific T cells recognise the omicron XBB sublineage. Lancet Microbe 2023;4:e388.
- Park K, Choi SJ, Shin EC. Omicron subvariants, including BA.4 and BA.5, substantially preserve T cell epitopes of ancestral SARS-CoV-2. Immune Netw 2022;22:e29.
- Choi SJ, Kim DU, Noh JY, Kim S, Park SH, Jeong HW, Shin EC. T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant. Cell Mol Immunol 2022;19:447-448. https://doi.org/10.1038/s41423-022-00838-5